Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials

Biliary tract cancer (BTC) compromises a heterogenous group of tumors with poor prognoses. Curative surgery remains the first choice for localized disease; however, most BTC patients have had unresectable or metastatic disease. The gold standard therapy for these patients is chemotherapy with gemcit...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Nai-Jung, Chen, Li-Tzong, Shan, Yan-Shen, Yeh, Chun-Nan, Chen, Ming-Huang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828560/
https://www.ncbi.nlm.nih.gov/pubmed/33451059
http://dx.doi.org/10.3390/biom11010097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828560/
https://www.ncbi.nlm.nih.gov/pubmed/33451059
http://dx.doi.org/10.3390/biom11010097

Ejemplares similares